Microencapsulated ferric chloride system
The microencapsulation of ferric chloride in sodium alginate capsules with vegetable oil buoyancy control addresses the inefficiencies of traditional HAB treatments, achieving targeted bloom removal and turbidity reduction with minimal ecological impact.
Patent Information
- Application Number
- PCT/US2026/026824
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Traditional methods for controlling harmful algal blooms (HABs) using ferric chloride are inefficient and cause immediate toxin release and oxygen depletion due to rapid cell lysis, while direct application in natural waterbodies poses handling challenges and ecological disturbances.
A microencapsulation system using sodium alginate capsules with embedded vegetable oil for buoyancy and pH-responsive dissolution, encapsulating ferric chloride to target cyanobacterial blooms, ensuring controlled release and aggregation of algae and phosphorus sequestration.
The system effectively removes cyanobacterial blooms and reduces turbidity by physically aggregating cells, minimizing toxin release and oxygen depletion, while maintaining ecological stability.
Smart Images

Figure US2026026824_12112026_PF_FP_ABST
Abstract
Description
[0001] Microencapsulated Ferric Chloride System
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This nonprovisional application claims priority to provisional application No. 63 / 800,809, entitled “Microencapsulated Ferric Chloride System,” filed on May 6, 2025, by the same inventors. BACKGROUND OF THE INVENTION
[0004] Field of the Invention
[0005] The present invention relates generally to compositions and methods for controlling harmful algal blooms (HABs), phosphorus concentrations, and turbidity in waterbodies. More specifically, the invention provides a microencapsulated ferric chloride system designed for controlled release triggered by elevated pH conditions characteristic of cyanobacterial blooms.
[0006] Brief Description of the Prior Art
[0007] Harmful algal blooms (HABs) present substantial ecological and public health challenges. Cyanobacteria, or blue-green algae, frequently dominate aquatic ecosystems, forming dense surface accumulations due to their buoyancy control via intracellular gas vesicles. These blooms degrade water quality, deplete oxygen, and release cyanotoxins detrimental to aquatic organisms and human health. Traditional control methods such as chemical algaecides rapidly lyse cells, causing immediate toxin release and oxygen depletion, exacerbating ecological damage.
[0008] Ferric chloride (FeCIs) is widely employed as a coagulant in water treatment, facilitating the removal of suspended solids and phosphorus by forming flocculant aggregates. However, its direct application in natural waterbodies poses handling challenges, rapid dilution, and potential ecological disturbances. Consequently, a controlled-release formulation ensuring targeted and environmentally responsive delivery is required.
[0009] While certain aspects of conventional technologies have been discussed to facilitate disclosure of the invention, Applicants in no way disclaim these technical aspects, and it is contemplated that the claimed invention may encompass one or more of the conventional technical aspects discussed herein.
[0010] The present invention may address one or more of the problems and deficiencies of the prior art discussed above. However, it is contemplated that the invention may prove useful in addressing other problems and deficiencies in a number of technical areas. Therefore, the claimed invention should not necessarily be construed as limited to addressing any of the particular problems or deficiencies discussed herein.In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not an admission that the document, act or item of knowledge or any combination thereof was at the priority date, publicly available, known to the public, part of common general knowledge, or otherwise constitutes prior art under the applicable statutory provisions; or is known to be relevant to an attempt to solve any problem with which this specification is concerned.
[0011] BRIEF SUMMARY OF THE INVENTION
[0012] The invention relates to a microencapsulation system for targeted control and mitigation of cyanobacterial blooms, phosphorus sequestration, and turbidity reduction in aquatic environments. The microcapsules described herein are primarily composed of sodium alginate (NaCeH Oe), a naturally derived polysaccharide obtained from brown algae. Concentrations of sodium alginate used typically range from about 1% to about 5% weight per volume (w / v), which provides control over capsule integrity and dissolution characteristics. Sodium alginate is chosen specifically for its biodegradability, biocompatibility, and responsiveness to changes in environmental pH, making it suitable for encapsulation and targeted payload delivery triggered by specific water chemistry conditions, particularly those associated with cyanobacterial blooms.
[0013] Buoyancy control within the alginate microcapsules is accomplished by emulsifying vegetable oil, such as corn oil or another vegetable oil, within the alginate polymer matrix. The vegetable oil is incorporated at concentrations ranging approximately from about 15% to about 30% volume per volume (v / v). These vegetable oil droplets, when distributed within the alginate matrix, reduce the overall density of the microcapsules. As a result, capsules maintain a position within the upper portion of the water column, typically within approximately one foot from the water surface. This buoyancy aligns capsule distribution with the typical location of cyanobacterial surface blooms, ensuring interaction and payload release within bloom zones. Capsule dissolution is specifically designed to occur under elevated pH conditions characteristic of active cyanobacterial blooms. During intense photosynthetic activity, cyanobacteria commonly elevate local surface-water pH. To exploit this condition, alginate capsules are engineered to dissolve within pH ranges of about 8.5 to about 11. Capsule dissolution rates may be adjusted through controlled variations in capsule wall thicknesses, alginate concentration, calcium crosslinking, buffer selection, and capsule size. The capsules are designed to remain stable under neutral to mildly alkaline conditions and to release payload when environmental pH reaches a selected bloom-associated threshold, such as about pH 8.5 or higher. Absolute dissolution rates may be confirmed for a selected formulation by laboratory testing.
[0014] Encapsulated within the microcapsules is ferric chloride (FeCIs), utilized as the active coagulant agent. Ferric chloride has proven effectiveness in water treatment due to its capability to bindcyanobacterial cells, suspended particulates, and dissolved phosphorus upon release. Concentrations of ferric chloride payload within capsules may range from about 50 mg / L to about 150 mg / L, and a representative current design incorporates a ferric chloride payload concentration of about 100 mg / L FeCIs. Testing has identified about 2 mg / L FeCIs as a minimum concentration to prompt coagulation of target algae. The capsules are intended to be dosed into a selected treatment volume so that final diluted ferric chloride concentrations remain below applicable ecological safety limits for the site.
[0015] Regarding storage and stability, encapsulation can improve handling by isolating ferric chloride within a hydrated capsule structure until deployment. Long-term storage conditions and shelf life may be established by additional testing. In short-term handling, capsules may be maintained hydrated at room temperature, while non-encapsulated ferric chloride is commonly stored as a dry powder in proper chemical storage. Deployment of encapsulated ferric chloride involves broadcast dispersion across surface areas affected by algal accumulations. Capsule deployment rates and dosages are calculated considering factors such as waterbody volume, treatment area, bloom extent and intensity, and the depth characteristics of the affected surface layer.
[0016] Laboratory evaluations and preliminary observations support formation of aggregates composed of cyanobacterial cells following ferric chloride treatment, with the aggregates exhibiting increased density relative to surrounding water and settling from the water column. This physical removal can also reduce turbidity and remove phosphorus-containing material from the treated water. Planned field evaluations may be used to confirm laboratory observations under site-specific conditions, including bloom response, water-quality changes, toxin behavior, dissolved oxygen response, and non-target ecological observations.
[0017] Preliminary comparative analyses indicate advantages over traditional chemical treatments such as algaecides. Unlike algaecides that result in rapid cell lysis and immediate release of intracellular toxins, the encapsulated ferric chloride method described herein physically aggregates cyanobacterial cells, allowing intact removal from the water column. This physical removal minimizes immediate toxin release risks and avoids significant oxygen depletion typically associated with rapid biomass decay.
[0018] The microcapsules are manufactured using a polymerization bath method. Initially, droplets containing an aqueous sodium alginate solution, ferric chloride payload, and buoyancymodifying vegetable oil are prepared and then introduced into an aqueous calcium chloride (CaCL) solution. The calcium chloride bath typically has a concentration of approximately 200 mM and contains a surfactant, such as Tween-20, at approximately 0.2% to reduce surface tension and ensure consistent capsule formation. Polymerization occurs at ambient temperatures, typically ranging from about 20°C to 25°C, over approximately one hour, during which sodium ions within the alginate are replaced by calcium ions through ion exchange. Thisprocess results in ionically crosslinked alginate capsules encapsulating the payload and buoyancy components, forming uniform microcapsules with consistent structural integrity. The manufacturing process outlined herein utilizes commonly available and environmentally compatible materials, facilitating production at scales suitable for various application scenarios, ranging from small ornamental water features to larger lakes and reservoirs. This method can be adjusted to accommodate larger production scales as required by operational demands, maintaining consistency in capsule properties and performance.
[0019] In summary, the microencapsulation system described herein provides targeted control of cyanobacterial blooms, phosphorus removal, and water turbidity reduction by leveraging environmentally responsive encapsulation technology. Sodium alginate capsules, responsive to bloom-induced pH elevation, effectively deliver ferric chloride directly into affected surface waters, promoting rapid algal aggregation, flocculation, and sedimentation. This approach significantly reduces cyanobacterial biomass and associated water quality issues while minimizing adverse ecological impacts typically associated with conventional chemical treatments.
[0020] In additional embodiments, the invention includes a treatment planning and deployment method in which an operator identifies a cyanobacterial bloom zone, measures environmental conditions associated with bloom activity, determines a target treatment volume or surface treatment zone, calculates a ferric chloride equivalent dose, selects a capsule blend having a selected buoyancy and dissolution profile, and distributes the capsules to the affected water surface. The method can be carried out manually, from a vessel, from a shoreline, by an automated dispenser, or by a floating deployment apparatus. The dosage determination may account for one or more of waterbody surface area, surface-layer depth, local pH, turbidity, chlorophyll-a, phycocyanin, visible bloom density, dissolved oxygen, phosphorus concentration, temperature, current, and wind-driven accumulation of bloom material. In this manner, the quantity of capsules is not merely a bulk addition of a chemical, but is an adaptive application of a stored coagulant payload to the portion of the water column in which buoyant cyanobacteria are concentrated.
[0021] In additional embodiments, the invention includes method steps for manufacturing true coreshell capsules and for verifying that those capsules are suitable for deployment. The manufacturing method may include preparing an alginate shell liquid, emulsifying vegetable oil into the alginate shell liquid, preparing a ferric chloride core liquid, loading the shell liquid and core liquid into separate reservoirs, feeding the liquids through a concentric nozzle at controlled rates, applying vibration to form discrete droplets, receiving the droplets in a calcium chloride polymerization bath, curing the resulting capsules, rinsing the capsules, and storing the capsules in a hydrated condition. The flow rates, nozzle geometry, vibration frequency, calcium chloride concentration, surfactant concentration, cure time, oil content, and alginateconcentration may be adjusted to control capsule diameter, shell thickness, payload loading, buoyancy, stability, and dissolution time.
[0022] In further embodiments, the invention includes post-treatment monitoring and optional retreatment. The monitoring may include establishing endpoint criteria, taking baseline and post-application water quality measurements, observing formation and settlement of flocculated algal aggregates, evaluating dissolved oxygen and toxin behavior, and applying a supplemental quantity of capsules when an endpoint has not been reached. Such monitoring is useful because harmful algal blooms can be spatially heterogeneous and can shift under wind, current, light, temperature, and nutrient conditions. The invention therefore includes not only the capsule composition, but also a controlled method of using the capsule composition in a manner that supports measured bloom removal and nutrient sequestration while avoiding unnecessary release of coagulant into portions of the waterbody that do not exhibit bloomtriggering conditions.
[0023] These and other important objects, advantages, and features of the invention will become clear as this disclosure proceeds.
[0024] The invention accordingly comprises the features of construction, combination of elements, and arrangement of parts that will be exemplified in the disclosure set forth hereinafter and the scope of the invention will be indicated in the claims.
[0025] BRIEF DESCRIPTION OF THE DRAWINGS
[0026] For a fuller understanding of the invention, reference should be made to the following detailed description, taken in connection with the accompanying drawings, in which:
[0027] Fig. 1A is a diagram of the microcapsule structure, showing the alginate polymer shell, vegetable oil emulsion droplets, and ferric chloride payload.
[0028] Fig. 1B is a diagram of a process to manufacture the alginate microcapsules via droplet formation and polymerization in a calcium chloride bath.
[0029] Fig. 2 displays a Microcystis colony with mucilage visible by staining, illustrating a mucilaginous sheath associated with colonial cyanobacteria and relevant to ferric chloride induced coagulation.
[0030] Fig. 3A through Fig. 3C display Microcystis response to ferric chloride treatment at about 30 minutes, 24 hours, and 48 hours, respectively, with treated samples shown on the left and untreated control samples shown on the right.
[0031] Fig. 4A is a flowchart of a treatment method for assessing a harmful algal bloom zone, calculating a capsule dosage, deploying buoyant pH-responsive capsules, triggering capsule dissolution, forming ferric chloride induced flocs, sedimenting coagulated aggregates, and conducting post-treatment monitoring.Fig. 4B is a flowchart of a capsule manufacturing method including alginate preparation, vegetable oil emulsification, ferric chloride core preparation, reservoir loading, controlled flow and vibration, core-shell droplet formation, calcium chloride bath solidification, curing, collection, rinsing, hydrated storage, and quality control release.
[0032] Fig. 4C is a flowchart of a post-treatment monitoring and adaptive retreatment method including baseline sampling, endpoint definition, interval sampling, water quality assessment, observation of floc and sediment behavior, comparison to end point criteria, dosage or buoyancy adjustment, supplemental deployment, and documentation of results.
[0033] DETAILED DESCRIPTION OF THE INVENTION
[0034] The present invention relates to a buoyant, pH-responsive microencapsulation system for mitigating harmful algal blooms in aquatic environments. In one embodiment, the invention provides a buoyant polymeric microcapsule (e.g., microcapsule 10 in FIG. 1A) designed to encapsulate a chemical coagulant and remain afloat near the water surface until triggered to release its payload under specific environmental conditions. The microcapsule comprises a crosslinked sodium alginate polymer matrix as its shell or body, which houses an iron-based coagulant (preferably ferric chloride, FeCIs) as the active payload and contains a dispersed light-density fluid (such as vegetable oil) to confer controlled buoyancy.
[0035] The capsule is formulated to be stable and retain its contents in neutral to mildly basic waters, but to undergo rapid disintegration and release the coagulant when ambient pH rises above a threshold (approximately pH 8.5). This pH threshold is characteristic of intense cyanobacterial (blue-green algal) blooms, which elevate the water's pH through photosynthetic activity. Upon dissolution of the capsule at high pH, the coagulant is liberated into the surrounding water, where it induces flocculation of algae and associated particulates. The resulting flocs (aggregated algae and coagulant precipitates) are denser than water and settle to the bottom, thereby removing the bloom from the surface and simultaneously sequestering nutrients (such as phosphorus) contained in the algal biomass. Unlike traditional algaecidal treatments that lyse cells and release toxins, this approach physically removes intact algal cells from the water column, mitigating immediate toxin release and avoiding sudden oxygen depletion from rapid biomass decay. By using a buoyant, pH-triggered delivery vehicle, the invention targets harmful blooms in situ with high specificity: capsules concentrate in the same surface layer as buoyant cyanobacteria and deploy their payload precisely when bloom conditions (high pH) are detected. This combination of features, buoyancy control, pH-triggered release, and coagulantbased flocculation, allows efficient, controlled mitigation of algal blooms and improved water quality.
[0036] Capsule Design and Composition
[0037] The buoyant microcapsule 10 (see FIG. 1A for an illustrative cross-sectional view) is engineered as a multi-component system optimized for stability, buoyancy, and targetedrelease. Its design integrates materials that serve distinct functions: the polymeric matrix forms the structural capsule, the coagulant provides the active bloom-treating agent, and the dispersed low-density phase imparts floatation. Key aspects of the capsule’s composition are as follows:
[0038] Polymeric shell matrix
[0039] The capsule is primarily composed of a hydrogel matrix formed by crosslinked sodium alginate. Sodium alginate is a natural polysaccharide (composed of mannuronic and guluronic acid monomer units) derived from brown algae, which gels in the presence of multivalent cations (such as Ca2+). In fabrication, an aqueous alginate solution (for example, about 1-5% w / v alginate) is crosslinked ionically to create a three-dimensional polymer network (shell 12) that holds the capsule’s contents. The resulting capsule is generally spherical and translucent, with a typical diameter on the order of a few millimeters (e.g., 1-5 mm, adjustable based on production parameters). The alginate matrix is biocompatible, environmentally benign, and naturally biodegradable, ensuring that any residual capsule material will break down over time.
[0040] Encapsulated coagulant payload
[0041] Dispersed or dissolved throughout the alginate matrix is the active coagulant agent, preferably ferric chloride (FeCIs). Ferric chloride is a well-known water treatment coagulant that, upon release into water, hydrolyzes to form iron(lll) hydroxide complexes which can adsorb and neutralize particulate matter and facilitate floc formation. In the capsule 10, ferric chloride (coagulant 16 in FIG. 1A) is incorporated typically as an aqueous solution mixed into the alginate prior to gelation, and may be encapsulated into the alginate matrix. For example, an alginate solution may be loaded with on the order of 0.01-0.1% w / v FeCIs (e.g., roughly 50-200 mg of FeCIs per liter of gel solution) to yield capsules containing a controlled quantity of coagulant. This corresponds to each capsule carrying on the order of micrograms of FeCIs (exact amount depends on capsule size and formulation). The concentration is selected such that, when a practical dose of many capsules is distributed in a target water body, the total iron introduced is sufficient to coagulate the bloom (typically a few milligrams per liter in the treated water) yet remains below ecological toxicity thresholds (i.e., below known LC50 levels for aquatic organisms). Importantly, the coagulant remains sequestered and inactive within the intact capsule, preventing any premature interaction with the environment until the moment of release.
[0042] Buoyancy control agent
[0043] To ensure the capsule 10 resides in the upper water column (ideally the top ~30 cm or one foot of water depth), a buoyant filler is incorporated into the capsule. In the preferred embodiment, this is achieved by emulsifying a small percentage of vegetable oil (such as soybean or corn oil) into the alginate solution before or during the capsule formation. The oil (indicated as element 18 in FIG. 1A) forms dispersed microscopic droplets embedded within the polymermatrix, effectively creating low-density inclusions (tiny oil-filled “chambers”) throughout the capsule. These oil inclusions reduce the overall density of the capsule relative to water. By adjusting the volume fraction of oil, the net buoyant force can be tuned: for instance, an oil content in the range of about 15-30% (v / v relative to the alginate mixture) has been found to produce capsules that are positively buoyant yet not so light that they entirely breach the water surface. The capsules typically float with neutral to slight positive buoyancy, meaning they remain suspended near the surface (often just submerged or partially floating) and move along with surface water currents. Vegetable oil is used for its availability, safety, and biodegradability, but other inert low-density materials (e.g., certain hydrocarbons or hollow microspheres) could similarly be used as described below. The buoyancy design ensures that after deployment, the capsules naturally congregate in the same region as surface-floating algae, maximizing contact when the payload is released.
[0044] pH-responsive stability modifier (optional)
[0045] In some embodiments, the alginate formulation may include pH-buffering or pH-sensitive additives within the polymer matrix to fine-tune the dissolution trigger point. For example, a weak acid or buffering salt can be co-incorporated so that the capsule remains stable at moderately alkaline pH (e.g., up to around pH 8) and only begins to break down when the ambient pH exceeds a higher threshold (e.g., above ~8.5-9). Alginate gels inherently weaken in high-pH conditions (as hydroxide ions can chelate calcium or break glycosidic bonds in the polysaccharide), but by including a buffer component, the capsule can resist premature softening. This means that under normal conditions (neutral pH or slight alkalinity), the capsule retains its integrity, whereas during a cyanobacterial bloom when pH spikes into the 8.5-10 range, the buffering capacity is overwhelmed and the alginate hydrogel rapidly disintegrates. As one example, incorporation of a bicarbonate or phosphate buffer within the alginate mix can serve to stabilize internal pH; only when the water’s pH is sufficiently high will the alginate crosslinks start to dissociate, causing the capsule to rupture and release the ferric chloride payload. Such modifications allow the threshold and response time of capsule dissolution to be tuned as needed for different environmental conditions or bloom severities.
[0046] Manufacturing Process (Polymerization Bath Method)
[0047] The microcapsules described herein are produced using an ionotropic gelation technique employing a concentric nozzle (CN) droplet-formation system followed by capsule solidification in a polymerization bath. This process is schematically depicted in FIG. 1B, clearly illustrating three primary process steps: (1) preparation of alginate solution (20) containing vegetable oil emulsion (18); (2) droplet formation via concentric nozzle configuration, creating droplets having an alginate-oil shell surrounding a liquid ferric chloride core; and (3) solidification of capsule shells (40) within a calcium chloride (CaCl2) polymerization bath (38). The described method is well-suited to scalable, controlled manufacturing of microcapsules with precisely defined structural and compositional properties.Preparation of alginate solution: Dry sodium alginate polymer is dispersed in water to yield an alginate solution (20) having a concentration typically ranging between approximately 1% to 5% weight per volume (w / v). Practically, about 10-50 g of sodium alginate may be added per liter of deionized water to produce a suitably viscous solution. This solution is thoroughly stirred and gently heated as necessary to achieve complete hydration and uniformity. Following alginate preparation, vegetable oil (18), such as soybean or corn oil, is emulsified into the alginate solution in controlled proportions, typically from about 15% to about 30% volume per volume (v / v). This emulsification may be achieved through vigorous stirring, homogenization, or sonication. Optionally, small amounts of emulsifiers or surfactants can be introduced to ensure stable and uniform dispersion of oil droplets throughout the alginate solution. The resulting alginate-oil emulsion (20 combined with 18) provides buoyancy control to the final microcapsules.
[0048] Incorporation of coagulant and buoyant phase: The iron coagulant (e g., FeCIs) and the buoyancy-adjusting oil (18) are separately prepared before encapsulation. A measured volume of ferric chloride solution (or solid FeCIs salt dissolved in a small amount of water) is prepared to achieve a desired FeCIs concentration, typically on the order of approximately 0.1 g per liter of alginate solution for a representative formulation. Separately, vegetable oil (such as corn oil or soybean oil) is added in a controlled proportion, typically around 15-30% by volume of the total alginate mixture. The vegetable oil is emulsified into the alginate solution (20) to disperse the oil as fine droplets (18), achieved by vigorous stirring, homogenization, or sonication. Optionally, a small amount of emulsifier or surfactant may be added to stabilize the oil droplets within the alginate solution. After emulsification, the alginate solution (20) contains a uniform suspension of finely dispersed oil droplets, forming the outer-shell liquid, which will subsequently encapsulate a distinct ferric chloride aqueous core solution, as illustrated in FIG.
[0049] 1B.
[0050] Droplet formation (Core-Shell Capsule Generation via Concentric Nozzle System): The encapsulation step converts the alginate-oil emulsion (20, 18) and the ferric chloride solution into discrete core-shell droplets using a concentric nozzle droplet-generation system as shown in FIG. 1B. The concentric nozzle system comprises an outer shell nozzle (22) and an inner core nozzle (24), both positioned within a concentric nozzle (CN) pulsation body (26). The alginate-oil emulsion (shell liquid) is delivered through a luer connection (32) to the outer shell nozzle (22), while the ferric chloride solution (core liquid) is delivered through a separate luer connection (30) to the inner core nozzle (24). A vibration unit (34), secured by a magnet holder (28) onto a carrier plate (36), provides controlled vibration, breaking the coaxially extruded streams into discrete droplets. The size of the generated droplets is tunable based on nozzle diameter and fluid flow rate; typically, needle gauges ranging from about 20-25 are used, yielding droplets of approximately 2-4 mm diameter. These droplets, having a clearly definedcore-shell structure (ferric chloride solution core encapsulated by alginate-oil shell), are then introduced directly into a polymerization bath (38) below the concentric nozzle assembly. Crosslinking in calcium chloride bath: The polymerization bath (38) contains a calcium chloride (CaCl2) solution at a moderate concentration, typically in the range of about 100-200 mM CaCl2. Optionally, the bath may include a small amount of surfactant (for example, approximately 0.1-0.2% Tween-20) to reduce surface tension and minimize droplet deformation or coalescence as they enter the bath solution. Upon contacting the calcium chloride solution, calcium ions diffuse rapidly into the alginate polymer shell of each droplet, initiating immediate ionic crosslinking. This crosslinking reaction solidifies the outer surface (40) of the capsule within seconds. Continued diffusion of calcium ions inward ensures complete and uniform capsule shell gelation. During this ionic crosslinking process, an ion-exchange reaction occurs wherein calcium ions replace sodium ions initially present in the alginate polymer chains, producing a mechanically stable, gelled capsule shell. Ferric chloride solution within the core remains isolated and fully encapsulated, preventing premature release or interaction. Capsules are allowed to cure fully within the calcium bath (38) for approximately 30-60 minutes, ensuring robust structural integrity and consistent capsule performance. Collection and rinsing: After curing, the solidified capsules are collected from the bath. This can be done by decanting through a sieve or using a mesh scoop to retrieve the beads from the solution. The capsules are then rinsed gently with clean water to remove excess surface calcium chloride and any unbound material. At this stage, the capsules are formed and loaded with the coagulant and oil as intended. They are soft, water-swollen hydrogel spheres.
[0051] Storage and handling: The finished capsules should be kept in a hydrated state until use to maintain their integrity. In practice, they can be stored immersed in water or in a moist container to prevent drying out. Storage at room temperature is generally sufficient for short-term stability (days to weeks). For longer-term storage, cooler temperatures (but above freezing) may help preserve the structure, and the storage solution can be formulated with a small amount of calcium salt to prevent decalcification of the gels over time. Because the encapsulated ferric chloride is in a stable, isolated form, it does not corrode or react with storage containers as it might if it were stored as a raw solution. Compared to un-encapsulated ferric chloride, which is typically stored as a crystalline solid or concentrated solution under controlled conditions, the encapsulated form offers improved handling safety and potentially improved shelf-life once the optimal storage conditions are determined. All ingredients (alginate, CaCl2, vegetable oil, etc.) are inexpensive and readily available, making the manufacturing process cost-effective. Furthermore, the method is easily scalable: large batches can be produced by increasing the volume of the bath and using multi-nozzle droplet generation systems, enabling industrial-scale quantities of capsules to be made for field deployment.
[0052] Deployment and Mode of ActionOnce manufactured, the capsules can be deployed directly into affected water bodies, targeting areas with known surface algal blooms. Deployment can be achieved by simply broadcasting (scattering) the capsules onto the water surface from a boat or shore, or via automated dispersal systems. Because the capsules are designed to float or remain in the top layer, they will naturally distribute themselves across the bloom area, driven by wind and water currents much like the algae they aim to treat. The capsules 10 thus mimic the movement of algal colonies, ensuring they stay co-located with the bloom. Their neutral buoyancy (residing in roughly the top 1 ft of the water column) means they do not sink away from the surface blooms, nor do they wash up ashore immediately, but rather drift and intermingle with the cyanobacterial mats and particles. Triggered release mechanism: The capsules remain intact and retain their payload as long as ambient conditions are below the trigger threshold. Under typical pre-bloom conditions, freshwater pH is around 7-8, at which the calcium alginate network remains stable and only slowly erodes. However, when a harmful algal bloom develops, intense photosynthetic activity by the algae can drive the local pH upward (it is not uncommon for dense daytime blooms to raise surface water pH to 8.5-10 or higher). As a capsule encounters water at such elevated pH (for example, a Microcystis surface scum on a sunny afternoon with pH —9.0), the alginate gel begins to break down rapidly. Chemically, the alkaline conditions cause partial deprotonation of the guluronic / mannuronic acid residues and can also precipitate calcium as CaCOs or Ca(OH)2, undermining the crosslinks that hold the gel together. The presence of any pH-buffering additives in the capsule can delay this process until the threshold pH is exceeded, at which point the capsule 10 disintegrates. This dissolution can occur on the timescale of minutes to hours once the critical pH is reached (depending on capsule size and exact composition; thinner or smaller capsules respond faster). When the capsule matrix falls apart, it releases the ferric coagulant and the encapsulated oil. The ferric chloride, upon mixing with the ambient water, immediately hydrolyzes: Fe3+reacts with water to form iron(lll) hydroxide and various hydroxy complexes, liberating H+in the process (which incidentally can locally neutralize some of the high pH). The ferric hydroxide precipitates as flocs - amorphous brown particulate matter - which avidly adsorbs algae cells, organic matter, and phosphate from the water. In effect, each capsule’s payload disperses into a cloud of micro-flocculants right at the site of the algal cells. Flocculation and sedimentation: The released iron hydroxide flocs agglomerate with the cyanobacteria, clumping cells together into larger floc aggregates. Individual planktonic algae cells (which are typically a few micrometers in size) become bound into floc particles that can reach millimeter or centimeter scale clusters. These composite aggregates (algae plus iron precipitate) have a density significantly greater than water, especially as gas vesicles in the cyanobacteria collapse or are entrained in heavy floc.
[0053] Consequently, the formerly buoyant algae lose their flotation capability and begin to sink. In preliminary laboratory observations, dosed cultures of Microcystis aeruginosa formed clumps, sank to the bottom of the culture, and did not resuspend over an extended observation period. The sinking rate and settled-floc characteristics may vary with capsule dose, ferric chloriderelease, bloom density, water chemistry, water movement, and floc size. The end result is that surface or near-surface bloom material can be converted into settled biomass on the benthic zone or into material that may be removed by filtration, vacuuming, or another collection technique in an artificial waterbody.
[0054] FIGS. 3A-3C illustrate Microcystis response to ferric chloride treatment at about 30 minutes, 24 hours, and 48 hours, respectively, with treated samples shown on the left and untreated control samples shown on the right. At the lake or pond bottom, the coagulated algal mass may remain relatively intact, as opposed to immediately lysed cell debris, and may undergo gradual decomposition. Nutrients contained in the algal cells, such as phosphorus and nitrogen, are transported out of the photic zone and sequestered in the sediments or in collected floc material. Toxins that the cyanobacteria produced, such as microcystins, are expected to be released more gradually than in treatments that rapidly lyse cells, thereby reducing the risk of acute toxin exposure following treatment.
[0055] Over days to weeks, natural processes such as bacterial degradation, sediment burial, dilution, and waterbody mixing may break down algal material and associated toxins in a controlled manner. Dissolved phosphorus that leaches from decaying biomass may be captured by iron-containing floc, which can bind phosphate and keep it immobilized. Thus, the treatment removes visible bloom material and improves water clarity while also sequestering nutrients that would otherwise support renewed growth. The vegetable oil released from the capsule is present in small quantities and can disperse or biodegrade; its primary purpose is to position the capsule in the bloom-associated surface layer.
[0056] After deployment and triggering, the capsules leave behind precipitated iron-containing minerals, coagulated algae, and small quantities of biodegradable oil rather than persistent synthetic capsule material. Because the method emphasizes coagulation and sequestration rather than rapid cell lysis, it is intended to reduce sudden oxygen demand and abrupt toxin release relative to treatments that kill or rupture the bloom in place. Field implementation of this method involves determining the appropriate dosage of capsules per area based on bloom intensity and water volume. For example, one can deploy a sufficient number of capsules to achieve an equivalent FeCIs dose of a few milligrams per liter in the surface layer of the bloom. Because each capsule carries a known amount of coagulant, the required quantity can be estimated; the capsules can be distributed evenly across the bloom extent or concentrated in problem spots, such as downwind accumulations of scum. After application, the site can be monitored for bloom clearing and for water chemistry changes, including pH, dissolved oxygen, and toxin concentrations, to evaluate treatment performance.
[0057] Additional Method Implementations (FIGS. 4A-4C)
[0058] FIGS. 4A-4C illustrate additional method implementations that may be practiced with the buoyant, pH-responsive microcapsule system described above. The illustrated steps are notlimited to a single order unless expressly required by a claim, and one or more steps may be omitted, repeated, combined, or performed by manual, semi-automated, or automated equipment. The reference numerals used in FIGS. 4A-4C continue afterthe reference numerals of FIGS. 1A and 1B. In particular, the method steps begin at reference numeral 42, since reference numeral 40 identifies shell solidification in FIG. 1B. The additional method drawings are provided to support practical deployment, scalable manufacture, and post-treatment monitoring ofthe microencapsulated ferric chloride system.
[0059] Referring first to FIG. 4A, a treatment method may begin with assessment of a harmful algal bloom zone 42. Assessment of the bloom zone 42 may include visual observation of a surface scum, remote imaging, sampling with a bucket or tube sampler, measurement of water clarity, measurement of pigment indicators, or identification of wind-driven accumulations along a shoreline, intake, marina, canal, pond edge, reservoir arm, fountain basin, or other quiescent portion of a waterbody. The assessment step 42 may also include determining whether the bloom is primarily surface-floating, dispersed through a shallow surface layer, or concentrated in discrete mats. Such information assists in selecting a quantity and buoyancy distribution of capsules that will reside in the same portion of the water column as the target algal biomass. The treatment method may then include measuring one or more waterbody conditions at step 44. The measured conditions may include pH, turbidity, Secchi depth or other clarity measurement, temperature, dissolved oxygen, conductivity, chlorophy ll-a, phycocyanin, total phosphorus, soluble reactive phosphorus, alkalinity, and any toxin or toxin-screening measurement appropriate for the waterbody. In one embodiment, pH is measured at or near the surface ofthe bloom during daylight conditions because cyanobacterial photosynthesis can increase local surface-water pH. Multiple measurements may be taken across the treatment area when the bloom is patchy or when wind concentrates bloom material in one location. Step 44 may also include recording a baseline condition before treatment so that the post-treatment response can be evaluated relative to pre-treatment water quality.
[0060] At step 46, an operator may determine a relevant treatment area and treatment depth. The treatment area may be the visible surface area of a bloom, the surface area of a selected water feature, or a portion of a lake, pond, reservoir, canal, marina, or intake zone that requires control. The treatment depth may correspond to a surface treatment layer in which buoyant cyanobacteria are concentrated, such as the upper one foot of the water column, or another shallow depth selected based on field conditions. The treatment volume may be approximated as the treatment area multiplied by the selected treatment depth. The method may also account for water movement, anticipated dilution, and whether the treatment area is a closed basin, a flowing canal, a nearshore accumulation, or an open water bloom. These values provide an operational basis for dose calculation while allowing the formulation to remain targeted to the bloom zone rather than to the entire waterbody volume.At step 48, a dosage may be calculated. In an exemplary embodiment, the dosage calculation may use a target ferric chloride equivalent concentration for the selected surface treatment volume and the known ferric chloride loading per capsule or per mass of capsules. For example, the quantity of capsules may be selected so that, after release and dilution within the target treatment layer, the ferric chloride concentration is sufficient to induce coagulation of cyanobacterial cells and suspended particulates while remaining below predetermined ecological safety limits for the site. The calculation may be expressed generally as the product of a target treatment volume and a target ferric chloride concentration divided by the available ferric chloride payload per capsule, optionally adjusted by a safety factor, bloom intensity factor, or expected dilution factor. In other embodiments, the dosage can be selected from a dosage table prepared from laboratory jar testing or from historical data for a particular waterbody type. At step 50, a capsule blend may be selected. The capsule blend may include capsules having different shell thicknesses, diameters, oil contents, payload loadings, or dissolution profiles. A formulation with a greater oil fraction may be selected where bloom material is strongly concentrated at the surface, while a formulation with lower positive buoyancy or near-neutral buoyancy may be used where cyanobacterial colonies are distributed through a shallow subsurface layer. Capsule blend selection may also be used to provide staged release. For example, a first fraction of capsules may have a thinner shell for faster release when pH exceeds the trigger threshold, while a second fraction may have a thicker shell or different buffer loading for delayed release during a sustained bloom event. Such blending permits treatment over a practical time window while preserving the principle that payload release is biased toward bloom-associated water chemistry.
[0061] At step 52, the selected capsules are dispersed onto or into the affected water surface. Dispersal may be performed by hand broadcast, a scoop, a shaker container, a spreader, a boat-mounted applicator, a pump-assisted dispenser, a floating buoy dispenser, a remotely controlled vehicle, or an aerial or shoreline distribution device. The capsules may be distributed substantially uniformly across a surface treatment area or may be concentrated in a downwind bloom accumulation. Because the active ferric chloride is encapsulated, handling and deployment may be more controlled than direct addition of an aqueous ferric chloride solution. The capsules may also be packaged in hydrated form, in measured units, or in cartridges configured to be released by an automated system when measured pH, turbidity, or pigment signals indicate a bloom condition.
[0062] Following dispersal, the capsules assume an upper-water-column position at step 54. The vegetable oil droplets or other buoyancy modifier within the alginate shell reduce the density of each capsule and help the capsule remain in the same region where buoyant cyanobacteria collect. Step 54 may include a drift period during which capsules move with surface currents and wind-driven water movement. This drift can be advantageous because cyanobacterial surface accumulations also move in response to wind and current. As a result, the capsulescan remain co-located with bloom material rather than sinking immediately below the target organisms. In some embodiments, the capsules are formulated to remain just submerged, thereby reducing loss to shorelines while still remaining in contact with the surface bloom. At decision step 56, the capsule encounters a trigger condition. In a preferred embodiment, the trigger condition is an elevated pH condition associated with active cyanobacterial photosynthesis, such as pH of about 8.5 or higher. When the pH remains below the selected threshold, the capsule may retain its ferric chloride payload and continue to drift or remain suspended within the upper water column. When the pH reaches or exceeds the selected threshold, the alginate shell begins to destabilize. The threshold may be tuned by shell thickness, alginate concentration, calcium crosslink density, pH-buffering additives, capsule diameter, and oil content. Thus, the trigger step 56 provides an environmental gate between storage or non-bloom conditions and release within bloom-associated conditions.
[0063] Once the trigger condition is satisfied, the shell dissolves or disintegrates at step 58. Dissolution may involve weakening of calcium alginate crosslinks, swelling of the hydrogel, erosion of the shell, rupture of the shell, or a combination of these effects. The dissolution rate can be selected to be fast enough to provide treatment during an active bloom event, while slow enough to avoid an uncontrolled pulse from every capsule immediately upon deployment. The method may therefore employ capsules having dissolution times selected for a particular application, such as a short dissolution time for a small ornamental pond or a longer dissolution time for a larger reservoir or marina in which drift and distribution are desired before full release.
[0064] At step 60, the ferric chloride payload is released into the water surrounding the target bloom. The released ferric chloride hydrolyzes and forms iron-containing species capable of binding algal cells, extracellular polymeric substances, suspended solids, organic matter, and dissolved or particulate phosphorus. The released ferric chloride may also locally reduce pH because hydrolysis produces hydrogen ions, which can counteract a portion of the bloom-associated alkalinity. The payload is preferably released close to the cyanobacterial biomass because the capsule has remained in the upper water column and because dissolution is triggered by elevated pH in the bloom zone. This proximity allows efficient use of the coagulant and reduces unnecessary treatment of water that is not associated with the bloom.
[0065] At step 62, algal cells and associated particulates coagulate and flocculate. The ferric species can neutralize surface charge, bridge between particles, and generate flocculent iron hydroxide material that entrains cyanobacteria, mucilage, suspended sediment, and phosphorus-containing material. In contrast to a treatment that functions primarily by lysing cells, the method of FIG. 4A promotes physical aggregation and removal of cells from the water column. The flocs may include intact cyanobacterial colonies, ferric hydroxide precipitates, extracellular mucilage, suspended solids, and adsorbed or precipitated phosphorus. Because the flocs are denser than the original buoyant cyanobacteria, the flocs begin to lose their tendency to remain near the surface.At step 64, coagulated aggregates sediment from the water column. Sedimentation may occur within hours or within a longer period depending on floc size, water movement, capsule dosage, and bloom density. The sedimented material may remain on the benthic substrate, may be collected by a filter or vacuum in an artificial waterbody, or may be retained in a settling zone. By moving algal biomass and bound phosphorus away from the photic surface zone, the method reduces the ability of the bloom to continue photosynthesis and also removes nutrients that would otherwise support renewed growth. The sedimented flocs can degrade slowly under natural conditions, thereby avoiding the rapid oxygen demand and toxin release often associated with direct algaecidal lysis.
[0066] At step 66, one or more post-treatment endpoints are monitored. Monitoring may include observing whether surface scum has decreased, measuring turbidity reduction, evaluating pH trends, measuring dissolved oxygen, observing floc deposition, and sampling phosphorus or toxin indicators. In some embodiments, the endpoint is a visible reduction in surface bloom density combined with a measured reduction in turbidity or pigment. In other embodiments, the endpoint may be based on nutrient reduction, maintenance of dissolved oxygen, absence of excessive toxin release, or satisfaction of site-specific water quality criteria. If the end point has not been reached, a re-dose decision may be made at step 68. A supplemental dose may be calculated using the same approach as step 48, while accounting for the amount of ferric chloride already deployed, the observed response, and any changes in bloom location or intensity.
[0067] FIG. 4B illustrates a method of manufacturing capsules suitable for the treatment method described above. The manufacturing method may begin with preparation of an alginate solution at step 70. Dry sodium alginate can be dispersed into water and hydrated until a substantially uniform solution is formed. The concentration may be selected within the previously described range of about 1% to about 5% by weight, with higher concentrations generally producing a more viscous shell liquid and potentially stronger capsule shells. Mixing time, hydration temperature, and order of addition may be controlled to reduce undissolved polymer particles and to provide consistent droplet formation during subsequent processing.
[0068] At step 72, vegetable oil is emulsified into the alginate solution. The oil may be introduced gradually while the alginate solution is stirred, homogenized, or otherwise mixed to create dispersed oil droplets throughout the shell liquid. The concentration of vegetable oil may be selected within the disclosed functional range of about 15% to about 30% by volume. Droplet size distribution within the emulsion can influence capsule buoyancy and shell uniformity. A surfactant or emulsifier may optionally be used to stabilize the oil droplets before droplet formation. The resulting shell liquid contains alginate for the hydrogel shell and oil droplets for buoyancy control.
[0069] At step 74, a ferric chloride core solution is prepared. The ferric chloride may be provided as a liquid solution or prepared by dissolving ferric chloride in water to a selected concentration. Theferric chloride concentration may be selected to provide a desired payload per capsule and a desired final ferric chloride equivalent concentration upon deployment. At steps 76 and 78, the shell liquid and core liquid are loaded into separate reservoirs. The shell reservoir communicates with the outer shell nozzle, and the core reservoir communicates with the inner core nozzle. Separate reservoirs permit independent control of the shell-to-core ratio, allowing capsule wall thickness and payload volume to be adjusted.
[0070] At step 80, flow and vibration parameters are set. The flow rate of the alginate-oil shell liquid, the flow rate of the ferric chloride core liquid, the nozzle diameter, the spacing between the nozzle and the polymerization bath, and the frequency or amplitude of vibration may be selected based on a target droplet diameter. Step 80 may also include setting temperature, bath agitation, and distance between droplets to reduce coalescence. At step 82, the concentric nozzle forms core-shell droplets in which the ferric chloride core is surrounded by the alginate-oil shell. The droplets are then received in the calcium chloride bath at step 84. Calcium ions in the bath diffuse into the alginate shell and initiate ionic crosslinking.
[0071] At step 86, the shell solidifies. Shell solidification may occur initially at the outer surface of the droplet and then proceed inward as calcium ions diffuse through the alginate. The solidified shell isolates the ferric chloride core from the external bath and provides a hydrogel structure capable of retaining the payload during storage and deployment. At step 88, the capsules are cured for a selected time, such as about 30 to 60 minutes, or another time sufficient to establish shell integrity. Agitation may be used to keep capsules separated and to promote uniform exposure to calcium ions. At step 90, the capsules are collected and rinsed to remove excess calcium chloride, surfactant, or unbound materials.
[0072] At step 92, the capsules are stored in a hydrated condition. Hydrated storage can preserve the hydrogel structure and reduce cracking or irreversible shrinkage. A storage solution may include water, a selected calcium concentration, or another compatible medium that maintains capsule integrity without causing premature release of the ferric chloride payload. At step 94, a quality control release decision may be made. Quality control can include measuring capsule diameter, confirming shell thickness or apparent shell continuity, checking buoyancy in water, measuring pH-triggered dissolution, confirming payload retention, and inspecting for broken capsules or excessive agglomeration. Capsules that satisfy the selected criteria may be released for field use, while capsules that fail the criteria may be reprocessed or discarded. FIG. 4C illustrates a post-treatment monitoring and adaptive retreatment method. At step 96, baseline sampling may be performed before or immediately at the time of treatment. Baseline sampling may include the water quality parameters described above and may also include photographs, surface scum mapping, or collection of untreated reference samples. At step 98, endpoint criteria are defined. Endpoint criteria may be established for a particular waterbody, use case, or regulatory or operational objective. Exemplary endpoints include reduction in visible surface scum, reduction in turbidity, reduction in phosphorus, downward trend inchlorophyll-a or phycocyanin, maintenance of dissolved oxygen above a selected level, and avoidance of an undesired toxin increase in the water column.
[0073] At step 100, the initial deployment is carried out using the selected capsule blend and dosage. At step 102, interval sampling is performed at one or more times after deployment. Sampling intervals may be selected based on expected capsule dissolution time, waterbody size, temperature, mixing, and bloom intensity. For example, an operator may sample within the first few hours to observe floc formation and may sample again after a longer period to assess sedimentation and water clarity. At step 104, water quality is assessed. Measurements may include pH, turbidity, dissolved oxygen, phosphorus, toxin indicators, conductivity, temperature, chlorophyll-a, phycocyanin, and visual observations. At step 106, floc and sediment behavior may be observed, including whether aggregates are forming, whetherthey are settling, whether the water column is clearing, and whether settled material is remaining on the bottom or is being resuspended.
[0074] At decision step 108, the observed response is compared to the endpoint criteria. If the end point criteria are satisfied, the results may be documented at step 114. Documentation may include dosage, capsule formulation, location, date, water quality measurements, photographs, and observations of floc and sediment behavior. Ifthe endpoint criteria are not satisfied, the method may proceed to step 110, where dosage or buoyancy is adjusted. Adjustment may include increasing or decreasing the capsule quantity, selecting capsules with a different buoyancy profile, selecting capsules with a different shell thickness or dissolution profile, or changing the spatial pattern of deployment. At step 112, a supplemental deployment may be performed. The method may then return to interval sampling at step 102 so that the effect of the supplemental deployment can be evaluated. This adaptive sequence allows the user to treat heterogeneous bloom conditions without relying on a single fixed application rate for every site.
[0075] Alternate Embodiment: Alternative Polymers for Capsule Shell
[0076] While sodium alginate is a preferred polymer due to its availability and built-in pH-sensitive degradation, other polymeric materials can be employed to construct the capsule shell with similar functional outcomes. In one alternate embodiment, the capsule’s hydrogel matrix is formed from carrageenan, a sulfated polysaccharide derived from red seaweed. Carrageenan (such as kappa-carrageenan) forms gels in the presence of certain ions (e.g., potassium or calcium) and can be processed in a manner analogous to alginate capsules: for example, a hot carrageenan solution containing the coagulant and oil could be dropped into a cool potassium chloride bath, causing it to gel into a capsule. Carrageenan capsules could be formulated to be thermally sensitive (melting and releasing contents if water temperature rises) or to slowly dissolve in water over time; their pH response may differ, but carrageenan is compatible with the same concept of buoyant coagulant delivery.In another embodiment, a chitosan-based capsule may be used. Chitosan is a cationic biopolymer obtained by deacetylation of chitin (from crustacean shells) and can form gel or shell structures via polyelectrolyte complexation. For instance, droplets of chitosan solution (with coagulant and oil) can be solidified by introducing them into a basic bath or a solution of multivalent anions (like sodium tripolyphosphate, TPP, which crosslinks chitosan). The resulting chitosan capsules would have somewhat different trigger properties: chitosan is stable in basic conditions and dissolves in acid (opposite to alginate). Such capsules might be useful if targeting scenarios where a drop in pH triggers release (for example, certain nighttime bloom conditions or in treatments where acidification occurs). Moreover, chitosan itself carries positive charges in neutral water and is known to act as a flocculant; thus, a chitosan capsule could synergistically enhance coagulation upon partial dissolution (releasing both FeCIs and soluble chitosan chains to bind algae). Other natural polymers like agar-agar, pectin, or gelatin, as well as synthetic hydrogels (e.g., polyacrylates or polyvinyl alcohol gels), could also be adapted as the capsule material, provided they can be engineered to remain intact in normal conditions and degrade in response to a chosen trigger (pH, temperature, enzymatic activity, etc.). These alternatives may require different crosslinking methods or trigger mechanisms (for example, agar capsules melting at a certain temperature, or a polymer that degrades under UV light), but they illustrate that the invention is not limited to alginate. The selection of polymer can be tailored to the environment: e.g., in saltwater applications, one might choose a polymer less sensitive to high ionic strength than alginate, or in a scenario without pH changes, one might use a light-degradable polymer triggered by sunlight intensity associated with blooms.
[0077] Alternate Embodiment: Alternative Deployment Methodologies
[0078] The manner in which the capsules are deployed and used can also be varied in alternate implementations of the invention. In one envisioned embodiment, the capsules are integrated into an automated floating dispensing system such as a smart buoy. This buoy could be equipped with water quality sensors (pH, algal pigment sensors, etc.) and a reservoir of capsules. When a bloom is detected (e.g., pH rises above a setpoint), the buoy automatically releases a measured batch of capsules.
[0079] In the aforementioned detailed description of the present invention, reference is made to the accompanying drawings, which form a part thereof, and within which are shown by way of illustration specific embodiments by which the invention may be practiced. Numerous specific details are set forth to provide a thorough description of the embodiments of the present invention. It will be apparent to one of ordinary skill in the art that some embodiments may be practiced without some of these specific details. It is to be understood that other embodiments may be utilized, and structural changes may be made without departing from the scope of the invention.As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and / or” unless the context clearly dictates otherwise.
[0080] All numerical designations, such as measurements, efficacies, physical characteristics, forces, and other designations, including ranges, are approximations which are varied up or down by increments of 1.0 or 0.1, as appropriate. It is to be understood, even if it is not always explicitly stated that all numerical designations are preceded by the term “approximately.” As used herein, “approximately” refers to being within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined. When an acceptable range is not dictated by the one of ordinary skill in the art, “approximately” refers to ±15% of the numerical when used in connection with particular values; it should be understood that a numerical including an associated range with a lower boundary of greater than zero must be a non-zero numerical, and the term “approximately” should be understood to include only non-zero values in such scenarios. The phrases “in some embodiments,” “according to some embodiments,” “in the embodiments shown,” “in other embodiments,” and the like generally mean the particular feature, structure, or characteristic following the phrase is included in at least one implementation. In addition, such phrases do not necessarily refer to the same embodiments or different embodiments. GLOSSARY OF CLAIM TERMS:
[0081] Algal blooms refer to rapid, often exponential proliferation of microscopic algae within aquatic ecosystems, resulting in visibly dense and extensive accumulations at or near the water surface. In the context of the present invention, algal blooms primarily involve cyanobacterial species, known for their buoyancy control mechanisms via gas vesicles. Cyanobacterial blooms are distinguished by their tendency to significantly alter local water chemistry, notably increasing pH levels through intensive photosynthetic activity. This elevation in pH triggers the dissolution mechanism of the microencapsulated ferric chloride capsules disclosed herein. These blooms negatively impact water quality by reducing transparency, oxygen availability, and causing ecological disturbances. Furthermore, cyanobacterial blooms can produce cyanotoxins harmful to aquatic life and human health. The invention specifically targets the mitigation of algal blooms by releasing ferric chloride, a coagulation agent, which aggregates cyanobacterial cells into dense flocs, facilitating their removal from the water column and subsequent sedimentation, thus addressing bloom proliferation and associated ecological concerns.
[0082] Algal coagulation is the process by which dispersed microscopic algal cells, particularly cyanobacteria, aggregate into larger flocs or clusters due to chemical treatment. In this invention, algal coagulation is induced by ferric chloride (FeCIs) released from themicroencapsulated system upon exposure to elevated pH levels characteristic of cyanobacterial blooms. The positively charged ferric ions interact electrostatically with negatively charged algal cells and suspended particulates, forming aggregates that substantially increase in size and density. These coagulated aggregates lose buoyancy, rapidly sinking to the sediment. This process is crucial for the invention as it facilitates efficient and ecologically safe removal of algae, simultaneously sequestering phosphorus and reducing turbidity, without causing the cell lysis typically associated with conventional chemical treatments. Thus, the controlled algal coagulation described herein significantly reduces bloom biomass and mitigates environmental consequences such as oxygen depletion and toxin release.
[0083] Cyanobacterial refers specifically to a group of photosynthetic bacteria, commonly termed blue-green algae, that are notable for their capability to produce dense blooms in aquatic ecosystems. Cyanobacteria have specialized cellular structures known as gas vesicles, enabling them to regulate buoyancy and remain at or nearthe water surface, optimizing access to sunlight. Cyanobacterial blooms significantly degrade water quality, consume oxygen during decomposition, and pose serious public health risks through cyanotoxin production. The invention explicitly targets cyanobacterial blooms by deploying buoyant, microencapsulated ferric chloride capsules into surface bloom regions. The capsules are activated by bloom-induced elevation in local pH, strategically releasing coagulants directly onto cyanobacterial colonies, causing cell aggregation and subsequent sedimentation without inducing cellular rupture or toxin release, thereby addressing cyanobacterial blooms at their source.
[0084] Emulsification is a process of creating a stable dispersion of small droplets of one immiscible liquid (such as vegetable oil) within another liquid (such as the aqueous sodium alginate solution). In the context of the present invention, emulsification is employed to integrate vegetable oil droplets uniformly within the sodium alginate polymer matrix. The vegetable oil is emulsified into the alginate polymer at concentrations between approximately 15% and 30% volume per volume (v / v), which significantly reduces the overall density of the microcapsule. This precisely controlled buoyancy allows capsules to float at the water surface, aligning their distribution with the cyanobacterial blooms' spatial occurrence. Effective emulsification ensures consistent capsule buoyancy, which is critical for maintaining capsule position at the optimal depth for targeted payload release and algal interaction.
[0085] Ferric chloride (FeCIs) is an inorganic coagulant used extensively in water treatment processes to induce aggregation of suspended solids and phosphorus removal. In the context of this invention, ferric chloride serves as the active payload encapsulated within the alginate polymer matrix. Upon capsule dissolution triggered by elevated pH conditions, ferric chloride hydrolyzes into iron hydroxide flocs, coagulating cyanobacterial cells, suspended particulates, and dissolved phosphorus. Ferric chloride payload concentrations may range from about 50 mg / L to about 150 mg / L, and dosage may be selected so that the final diluted concentration in theselected treatment volume is sufficient to prompt coagulation while remaining below applicable ecological safety limits.
[0086] Microencapsulated describes the encapsulation technique employed by this invention, wherein small quantities of active chemical agents (in this case, ferric chloride) are enclosed within microscopic spherical structures or capsules. The capsules are formulated from sodium alginate and designed to release their contents under specific environmental triggers, such as elevated pH conditions typical of cyanobacterial blooms. Microencapsulation ensures that the active agents remain inactive and isolated until targeted environmental conditions trigger their release. This controlled release mechanism maximizes treatment efficiency, minimizes chemical waste, and enhances environmental safety by avoiding indiscriminate chemical dispersion. Microencapsulation also significantly improves the handling, storage stability, and application precision of chemical payloads in aquatic environments.
[0087] Polymer shell in this invention refers to the outer protective structure of the microcapsules, specifically formulated from crosslinked sodium alginate. This polymer shell provides structural integrity, controls capsule buoyancy, and regulates payload release. The shell thickness, typically between 0.5 mm and 3 mm, significantly influences the dissolution kinetics, determining the precise environmental conditions under which capsules release their encapsulated agents. The alginate polymer shell is formed by ionic crosslinking, specifically the ion exchange of calcium ions replacing sodium ions within alginate, establishing robust capsules capable of maintaining structural stability until triggered dissolution. The polymer shell thus directly facilitates targeted payload deployment, ensuring treatment agents are released specifically within cyanobacterial bloom zones, thereby maximizing efficiency and ecological compatibility of the intervention.
[0088] Sodium alginate is a naturally derived polysaccharide (NaCeH Oe) extracted from brown algae, used in the invention as the primary encapsulation polymer. Sodium alginate exhibits beneficial characteristics including biodegradability, non-toxicity, and responsiveness to changes in pH, particularly relevant for targeted capsule dissolution. Within this invention, sodium alginate is prepared at concentrations ranging from about 1% to 5% weight per volume (w / v), providing a balance between structural integrity, dissolution control, and environmental responsiveness. Upon exposure to alkaline conditions typically exceeding a pH of 8.5, the alginate polymer matrix is configured to break down, enabling targeted payload release directly into areas affected by cyanobacterial blooms. Sodium alginate therefore provides controlled release triggered by water chemistry conditions indicative of harmful algal blooms.
[0089] Vegetable oil in the context of this invention refers to oil derived from corn or another vegetable source, utilized as a buoyancy modifier within the sodium alginate capsules. Incorporated at concentrations between approximately 15% to 30% volume per volume (v / v), vegetable oil lowers the capsule density and assists buoyancy within the upper portion of aquatic environments, such as the top one-foot layer. This buoyancy corresponds to the verticaldistribution pattern of surface-dwelling cyanobacteria and enhances treatment accuracy. Vegetable oil is selected due to its biodegradability, ecological compatibility, and ability to be emulsified within the alginate polymer matrix. Upon capsule dissolution and payload release, vegetable oil is present in small quantities and can disperse or biodegrade. Thus, vegetable oil plays a functional role in controlling capsule buoyancy and distribution for optimized environmental interaction and payload deployment.
[0090] Capsule blend refers to a group or batch of microcapsules selected for combined use in a treatment event, wherein the group may include capsules having different buoyancy, shell thickness, diameter, ferric chloride loading, dissolution threshold, or dissolution time. A capsule blend allows an operator to match capsule behavior to a bloom condition, such as a surface scum, a shallow subsurface accumulation, or a sustained bloom having variable pH over a treatment period. In some embodiments, a capsule blend contains a first capsule population configured for relatively rapid release and a second capsule population configured for delayed or slower release, thereby providing staged coagulation without abandoning the pH-triggered release principle.
[0091] Treatment dosage refers to the amount of microencapsulated ferric chloride composition applied to a selected treatment zone. The dosage may be expressed as a number of capsules, mass of hydrated capsules, volume of capsule slurry, ferric chloride equivalent mass, or ferric chloride equivalent concentration in a target surface treatment volume. In the context of this invention, treatment dosage may be calculated from the surface area of the bloom, the target treatment depth, the ferric chloride payload per capsule, bloom intensity, turbidity, pH, phosphorus concentration, and desired safety factor. Treatment dosage is preferably selected to induce coagulation and sedimentation while avoiding excessive introduction of coagulant to portions of the waterbody not requiring treatment.
[0092] Upper-water-column positioning refers to the buoyancy-controlled location of the microcapsules in the waterbody after deployment and before release of the ferric chloride payload. The capsules are designed to remain near the surface or within a shallow treatment layer, such as the top approximately one foot of water, so that the capsules remain co-located with buoyant cyanobacterial colonies and surface accumulations. Upper-water-column positioning may be achieved by incorporating vegetable oil droplets or other low-density inclusions in the polymer shell, by selecting capsule diameter, by adjusting shell density, or by selecting a capsule blend having multiple buoyancy profiles.
[0093] Endpoint criteria refer to one or more selected observations or measurements used to determine whether a treatment event has reached a desired result. Endpoint criteria may include visible reduction of a bloom, reduced turbidity, reduced chlorophyll-a or phycocyanin signal, reduction of soluble reactive phosphorus or total phosphorus, formation and sedimentation of flocs, maintenance of dissolved oxygen, stabilization or reduction of pH, and absence of an unacceptable increase in cyanotoxin concentration. Endpoint criteria may beused to determine whether supplemental capsules should be applied or whether treatment should be terminated and monitored without additional deployment.
[0094] The advantages set forth above, and those made apparent from the foregoing description, are efficiently attained. Since certain changes may be made in the above construction without departing from the scope of the invention, it is intended that all matters contained in the foregoing description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
[0095] It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention that, as a matter of language, might be said to fall therebetween.
Claims
AMENDED CLAIMSreceived by the International Bureau on 04 September 2026 (04.09.2026)
1. A composition comprising:a. a microcapsule comprising a sodium alginate polymer shell;b. vegetable oil emulsified within the sodium alginate polymer shell in concentrations from about 15% to 30% (v / v); and c. an aqueous ferric chloride payload encapsulated within said polymer shell, said aqueous ferric chloride payload having a ferric chloride concentration of about 50 mg / L to about 150 mg / L;wherein said aqueous ferric chloride payload forms a discrete liquid core surrounded and enclosed by said sodium alginate polymer shell, said vegetable oil being emulsified within said sodium alginate polymer shell.
2. The composition of claim 1, wherein the sodium alginate concentration is about 1% to 5% by weight.
3. The composition of claim 1, wherein the sodium alginate polymer shell dissolves at pH levels of about 8.5 or higher.
4. The composition of claim 1, wherein said vegetable oil renders said microcapsule positively buoyant such that said microcapsule remains within an upper one foot of a water column.
5. The composition of claim 1, wherein said microcapsule has a diameter of about 1 mm to about 5 mm.
6. A capsule blend comprising a first capsule population and a second capsule population, each of said first and second capsule populations comprising the composition of claim 1, wherein said first capsule population has a first buoyancy or dissolution profile and said second capsule population has a second buoyancy or dissolution profile different from the first buoyancy or dissolution profile.
7. A method for controlling cyanobacterial algal blooms comprising:a. dispersing a microencapsulated composition onto the surface of a water body experiencing elevated pH conditions characteristic of cyanobacterial blooms, said microencapsulated composition comprising a microcapsule comprising a sodium alginate polymer shell, vegetable oil emulsified within the sodium alginate polymer shell in concentrations from about 15% to 30% (v / v), and an aqueous ferric chloride payload encapsulated within said polymer shell, said aqueous ferric chloride payload having a ferric chloride concentration of about 50 mg / L to about 150 mg / L;b. allowing the sodium alginate polymer shell to dissolve;c. releasing ferric chloride;d. coagulating algal cells; ande. sedimenting coagulated aggregates.
8. The method of claim 7, wherein the ferric chloride release occurs at pH levels from about 8.5 to 11.
9. The method of claim 7, wherein coagulated aggregates sediment within 24 hours post-application.
10. The method of claim 7, further comprising monitoring toxin release and dissolved oxygen levels post-treatment.
11. An apparatus for producing microencapsulated ferric chloride capsules, the apparatus comprising:a. a concentric nozzle droplet formation system comprising an outer shell nozzle and an inner core nozzle;b. a first reservoir in fluid communication with the outer shell nozzle, said first reservoir containing a shell liquid comprising sodium alginate at concentrations from about 1% to about 5% by weight and vegetable oil emulsified within said sodium alginate in concentrations from about 15% to about 30% volume per volume (v / v);c. a second reservoir in fluid communication with the inner core nozzle, said second reservoir containing a core liquid comprising ferric chloride at concentrations from about 50 mg / L to about 150 mg / L; d. a vibration unit operatively connected to said concentric nozzle droplet formation system, said vibration unit configured to induce pulsations sufficient to produce discrete droplets, each droplet comprising a core of said ferric chloride solution surrounded by a shell comprising said sodium alginate and emulsified vegetable oil; and e. a polymerization bath comprising calcium chloride at concentrations from about 100 mM to about 200 mM positioned to receive said discrete droplets and induce ionic crosslinking of the sodium alginate shell, forming solidified microcapsules.
12. The apparatus of claim 11, wherein said polymerization bath further comprises a surfactant at a concentration of about 0.1% to about 0.2%, sufficient to reduce surface tension and prevent droplet deformation during shell solidification.
13. The apparatus of claim 11, wherein said concentric nozzle droplet formation system further comprises a magnet holder and carrier plate configured to support said vibration unit and provide controlledpositioning of said concentric nozzle relative to said polymerization bath.
14. The apparatus of claim 11, wherein the outer shell nozzle and inner core nozzle are connected via separate luer connections to their respective reservoirs, configured to independently control the flow rates and proportions of shell liquid and core liquid for adjustment of droplet size and capsule dimensions ranging from about 1 mm to about 5 mm in diameter.
15. The method of claim 7, further comprising, before dispersing the microencapsulated composition, determining a treatment dosage based on at least one of a surface area of the water body, a target treatment depth, bloom intensity, pH, turbidity, chlorophyll concentration, phycocyanin concentration, phosphorus concentration, temperature, water movement, or a ferric chloride payload per capsule.
16. The method of claim 15, further comprising selecting a capsule blend comprising a first capsule population having a first buoyancy or dissolution profile and a second capsule population having a second buoyancy or dissolution profile different from the first buoyancy or dissolution profile.
17. The method of claim 7, wherein the microencapsulated composition remains in an upper one foot of the water column before dissolution and releases ferric chloride after the sodium alginate polymer shell encounters a pH of about 8.5 or higher.
18. A method of producing microencapsulated ferric chloride capsules, the method comprising:a. preparing an alginate shell liquid;b. emulsifying vegetable oil into the alginate shell liquid;c. preparing a ferric chloride core liquid;d. delivering the alginate shell liquid through an outer shell nozzle of a concentric nozzle droplet formation system;e. delivering the ferric chloride core liquid through an inner core nozzle of the concentric nozzle droplet formation system;f. applying vibration to form core- shell droplets;g. receiving the core-shell droplets in a calcium chloride polymerization bath;h. curing the core-shell droplets to form solidified microcapsules; i. collecting and rinsing the solidified microcapsules; andj. storing the solidified microcapsules in a hydrated condition.
19. The method of claim 18, further comprising adjusting at least one of an alginate concentration, vegetable oil concentration, ferric chloride concentration, shell liquid flow rate, core liquid flow rate, nozzle diameter, vibration frequency, calcium chloride concentration, surfactant concentration, or cure time to control at least one of capsule diameter, shell thickness, payload loading, buoyancy, or pH-triggered dissolution time.
20. The method of claim 7, further comprising establishing endpoint criteria, measuring at least one water quality parameter after dispersing the microencapsulated composition, observing floc formation or sedimentation, comparing the at least one water quality parameter or observation to the endpoint criteria, and applying a supplemental quantity of the microencapsulated composition when the endpoint criteria are not satisfied.[0001]STATEMENT UNDER ARTICLE 19 (1)[0002]Claims 1 to 20 as filed are replaced by amended claims 1 to 20. Claims 1, 3, 7, 11, 15, 17 and 18 are amended, claims 4 to 6 as filed are cancelled and replaced by new claims 4 to 6, and claims 2, 8 to 10, 12 to 14, 16, 19 and 20 are unchanged.[0003]Amended claim 1 recites that the aqueous ferric chloride payload forms a discrete liquid core surrounded and enclosed by the sodium alginate polymer shell, with the vegetable oil emulsified within that shell. The core-shell structure is shown in Fig. 1A and is produced by the process of Fig. IB.[0004]US 2016 / 0244342 Al to Bezbaruah et al. describes an iron-functionalized alginate in which the iron is bound to, chelated with, or distributed as nanoparticles throughout the polymer, and does not describe a discrete liquid ferric chloride core enclosed by a sodium alginate shell. CN 107759326 A to Changzhou describes a preparation method for a sodium alginate and chitosan microcapsule foliar fertilizer in which petroleum ether is added to remove the oil phase before the product is centrifuged, washed and vacuum dried, and does not describe such a core. Hao et al. describes dosing ferric chloride, with a microbial flocculant, into bulk water, and does not describe an encapsulated payload.[0005]New claims 4 to 6 recite, respectively, positive buoyancy such that the microcapsule remains within an upper one foot of a water column, a microcapsule diameter of about 1 mm to about 5 mm, and a capsule blend of two populations having different buoyancy or dissolution profiles.[0006]Claim 7 is placed in independent form, reciting the composition of claim 1 as filed rather than referring to it, so the amendment to claim 1 does not narrow claim 7, whose scope is otherwise unchanged. In claims 7 and 15, "waterbody" is corrected to "water body," consistent with the description and with the observation in Box No. VIII of the written opinion. In claims 3, 7 and 17, "the capsule shell" is replaced by "the sodium alginate polymer shell" to conform to claims 1 and 7.[0007]Claim 11 is amended so that the first and second reservoirs are recited as containing the shell liquid and the core liquid rather than as configured to contain them, and the polymerization bath is recited as positioned to receive the discrete droplets.[0008]In claim 18, the three actions recited together in step f as filed are set out as separate steps f, g and h, and the following steps are relettered i and j. The wording and order are unchanged and no step is added or removed.[0009]No new matter is added. The amendments require no change to the description or to the drawings.
